Evidence map›Paper›PMID 42500682›Full record

ReviewFrontiers in immunology2026

Colorectal cancer liver metastases: mechanism and therapy.

Shan Liu, Liuxian Ban, Wei Zhang, Yutian Sun, Ke Wang, Yuxin Man, Yinjie Zhang

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shan Liu *Department of Radiation Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Liuxian Ban *Department of Clinical Oncology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Wei ZhangDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Yutian SunDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Ke WangDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Yuxin ManDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.
Yinjie ZhangDepartment of Medical Oncology, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer (CRC) is a leading cause of cancer mortality worldwide, with liver metastasis representing the principal cause of death in CRC patients. Current primary treatment options for colorectal cancer liver metastases (CRLM) encompass chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, the survival rate for CRLM patients remains below 40%. The unique immune-tolerant microenvironment of the liver has recently been recognized as a central driver of metastatic colonization, immune evasion, and therapeutic resistance. This review examines the development of CRLM, with particular emphasis on recent therapeutic advances. It also explores promising research and emerging treatment strategies. A deeper understanding of CRLM pathogenesis and therapeutic progress will enable clinicians to optimize treatment approaches and improve patient outcomes.

Indexed as

Colorectal NeoplasmsLiver NeoplasmsAnimalsHumansImmunotherapyTumor Microenvironmentcolorectal cancer liver metastaseshepatic immune microenvironmentimmunosuppressive nicheimmunotherapy resistanceMSS/pMMR

Identifiers

PMID42500682
PMCPMC13395994

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.